Shari Daniels

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Matthew Mei, Lu Chen, James Godfrey et al. · Blood · 2023 · 40 citations · Full text

Medicine, Oncology, Pharmacology +16

Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study

Alex F. Herrera, Jasmine Zain, Kerry J. Savage et al. · The Lancet Haematology · 2024 · 20 citations

Medicine, Hematology, Oncology +10

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Alex F. Herrera, Lu Chen, Jennifer L. Crombie et al. · Blood · 2022 · 18 citations

Medicine, Oncology, Pharmacology +10

Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma

James Godfrey, Matthew Mei, Lu Chen et al. · Haematologica · 2023 · 18 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17